NUNAGEN
NUNAGEN
ADVANCING SYNTHETIC GENOME PLATFORMS
THE NUNAGEN TEAM
We are a multidisciplinary collective of bioengineers, clinical researchers, and biotech visionaries. Our mission is to harness NUNAGEN’s synthetic gene platforms to pioneer a new era of sustainable, self-manufacturing therapeutics that optimize treatment delivery and transform global healthcare accessibility.
Founder
Dr Kourosh H. Ebrahimi
Founder and Chief Executive Officer
Dr Kourosh H. Ebrahimi is the Founder and Chief Executive Officer of NUNAGEN. A biotech innovator with over 15 years’ experience across academia and industry, he leads the vision and strategy behind NUNAGEN’s synthetic genome platforms. Kourosh brings together deep expertise in molecular biology, biocatalysis, and immunology with a focus on building scalable, sustainable technologies that can transform how therapies and preventive solutions are designed, manufactured and delivered to patients.
Expert Council
Professor William James
virology and immunology / University of Oxford
Professor William James serves as Senior Scientific Advisor to NUNAGEN. Drawing on decades of work in virology and immunology, he guides the strategic direction of our synthetic genome platforms, ensuring they are grounded in rigorous science and aligned with emerging clinical needs. His advisory role bridges academic discovery and translational development, helping NUNAGEN build therapies and preventive solutions with real-world impact.
Dr Jack Tan
Virology and Immunology / University of oxford
Dr Jack Tan acts as Scientific Advisor to NUNAGEN on therapeutic frameworks and molecular design. With expertise in virology and immunology, he supports the translation of our synthetic genome concepts into robust therapeutic strategies and delivery approaches. His advisory input helps shape platform design, risk assessment and experimental priorities, ensuring our programmes are both scientifically rigorous and clinically relevant.
Dr Igor Vivanco
Cancer biology / King's College London
Dr Igor Vivanco advises NUNAGEN on cancer biology and translational strategy. Bringing deep experience in tumour genetics and pathway biology, he helps align our synthetic genome platforms with the most relevant oncology use cases. His guidance informs target selection, model systems and validation strategies, ensuring our programmes are designed to address real clinical gaps in cancer care.
​
​
Dr Richard Amison
Pharmacology / King's College London
Dr Richard Amison advises NUNAGEN on pharmacology and preclinical development. With expertise in drug mechanism, dosing and safety, he helps shape how our synthetic genome platforms are evaluated in relevant models. His advisory role supports study design, biomarker strategy and interpretation of pharmacological data, ensuring our programmes move forward with a strong evidence base for future clinical translation.
Dr Omar Butt
healthcare innovation expert / King's College London
Dr Omar Butt advises NUNAGEN on healthcare innovation and system-level adoption. With experience across clinical innovation, digital health and service design, he helps position our synthetic genome platforms within real-world care pathways. His advisory role focuses on scalability, implementation and stakeholder engagement, ensuring that NUNAGEN’s technologies are designed not only to work in the lab, but to be adopted across health systems at scale.